Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There certainly is something significant going on with the ampakine platform. Of course the upcoming phase 2 SCI trial is a huge deal, especially at a premier institution and with government funding. In past filings or commentary they have highly suggested a clinical trial with ADHD would be right on the heels of this SCI trial. ADHD is a huge underserved market.
It is also becoming clear with the recent publications and due diligence here that they are summarizing anything and everything related to their ampakine platform efforts. Much of this work looks to have been completed a long time ago. So maybe they are just bored, but what would be a logical and reason to do as such is they are planning on moving the ampakine platform. Either to a new entity similar to OSA program or someone is looking to acquire the platform which would make more sense to me. Reason is I think it is at the stage where BP can take over and get these drugs into phase 3 efforts. RSPI does not have the resources to go much beyond this upcoming clinical trial. I also am wondering if there isnt enough data and clinical efforts that could suggest ADHD move into phase 3, since they have already completed a phase 2 I believe.
Thoughts?
Folks,
I have come a long way in understanding just what is going on in RSPI over the last few months. Years ago, I heavily invested in Cortex and lost big time! I understood the extraordinary potential of ampakines but I was obviously premature in investing. RSPI has taken the Cortex's ampakine pipeline and made many of the neurologically active molecules available to neurology-studying groups all over the world and reaped the benefits. This month I am blow away!!! There are so many paths now open with so many molecules it is absolutely ASTOUNDING that we are still sub penny! I have been investing in biotech for many years and have never seen anything like RSPI - not even close! IMO RSPI has to be worth billions. I think the best route for RSPI is partnering with a mega pharmaceutical and not selling their pipeline. It will be when RSPI announces a deal is when we will skyrocket.
Preclinical characterization of a water-soluble low-impact ampakine prodrug*, CX1942 and its active moiety**, CX1763
Daniel P Radin 1, Sheng Zhong 2, Rok Cerne 1, Mohammed Shoaib 3, Jeffrey M Witkin 1, Arnold Lippa 1
DOI: 10.1080/17568919.2024.2401312 Published Sept 20, 2024
Abstract
Aim: AMPA-glutamate receptor (AMPAR) dysfunction mediates multiple neurological/neuropsychiatric disorders. Ampakines bind AMPARs and allosterically enhance glutamate-elicited currents. This report describes the activity of the water-soluble ampakine CX1942 prodrug and the active moiety CX1763.Results: CX1763 and CX1942 enhance synaptic transmission in hippocampi of rats. CX1763 increases attention in the 5CSRTT in rats and reduces amphetamine-induced hyperactivity in mice. CX1942 potently reverses opioid-induced respiratory depression in rats. CX1942/CX1763 was effective at 2.5-10 mg/kg. CX1763 lacked epileptogenicity up to 1500 mg/kg in rats.Conclusion: These data document that CX1942 and CX1763 are active and without prominent side effects in multiple pre-clinical assays. CX1942 could serve as a prodrug for CX1763 with the advantage of high water solubility as in an intravenous formulation.
* a biologically inactive compound which can be metabolized in the body to produce a drug.
** Moieties are branches in organic molecules that extend from the carbon backbone. Often, moieties may be substituted with other substituents or side chains. In pharmacology, an active moiety is the portion of an ion or molecule responsible for the activity of a drug.
I believe the company keeps otcmarkets up to date.
Since there isn't up to date financial information, would they have any of the information you ask for?
I would think that they would only have the information after the company files all the delinquent paperwork with the SEC.
Need to call the Transfer Agent to get the accurate float and share structure. Can also email transfer agent.
Unrestricted seems to be hidden. Contacting the transfer agent is completely acceptable and a good DD action for any penny stock trader. The float is shares outstanding minus unrestricted. That's the stock that trades publicly.
Fidelity shows only 365 million O/S.
No, the shares outstanding which is 936 million according to otcmarkets, should encompass all shares being held by insiders, institutional, retail bums like all of us here, etc.
For sake of easy math, just say there is 1 billion shares floating around. Every penny in stock price is 10 million in valuation. Todays valuation is 2 million. Hence the opinions of many for a pharma with gov funding in phase 2 and likely more funding for a phase 1 coming, these valuations seem ultra low.
Nickels and dimes come and still would not be valued like some past storied pharmas or even some current OTC pharmas that have much less potential in business model/pipeline.
Being a somewhat of a dufus when it comes to the stocks, does:
"Shares Outstanding 471,740,000 shares" mean that more than 500,000,000 shares are being held by RSPI insiders?
lol.... maybe we are indeed the ones confused and in need of brain treatments...
On the surface it appears like there are some serious collaborators, premier institutions and medical professionals assoicated with this pipeline and these folk have successfully developed some premier compounds that have shown much early clinical and preclinical success to be considered premier candidates for drug development in human trials....
Yet the brain can not comprehend the current status of no liquidity and zero effort to build awareness to successfully move on these premier compounds...
Is there a CX-XXX compound for confusion? lol
Not sure it matters much. With zero liquidity any trades are merely at the whims of the few who have access to trade this on the expert market.
Considering this traded up to .007 ( a whopping 7 million market valuation which is way undervalued in my opinion) on just the announcement of a DOD funded phase 2 trial... What could this trade at when they begin this trial in Q4 and hopefully update us on the status of the gabakine program with successful tier 3 preclincals that is likely to get grant funding and into human trials as well?
Bidding a can of peanuts and asking for 3 cans of peanuts is still trading peanuts... Not going to interest very many folk.
0.002 62,200
0.0005 450,000
Damn I wonder if we slap past 002 what’s the next ask
The risk we humans run to get healthier
10K 0.002
10K 0.0004
Practically no bid x ask.
What’s bid and ask now?
I think we should all be concerned that with our input of Trumpian logic that these lab rats treated with CX-929 will become self-aware and thus plot to kill their human captors.
I'll buy more if and when we are off the EM.
lol. Maybe rather than do any updates, they should just hand out some type of ampakine to all who are currently scratching their heads?
As a scientist in this extremely competitive discipline, and if working with ampakine like CX-929, would I self-administer to improve my cognition? You bet! I have no doubt that off clinical trial application is occurring.
Enhancing Cognition through Pharmacological and Environmental Interventions: Examples from Preclinical Models of Neurodevelopmental Disorders
Lorenzo Morè1*, Julie C. Lauterborn2*, Francesco Papaleo3 and Riccardo Brambilla
Open Access document downloaded from ORCA, Cardiff University's institutional repository: https://orca.cardiff.ac.uk/id/eprint/119438/
[ca. 2019]
Effects of CX929 treatment on behavior were particularly striking, with the ampakine improving both long-term memory and self-organizing behavior. For these studies an unsupervised learning paradigm was used in which animals were allowed 30 min to freely explore a large arena that was divided into “rooms” containing unique objects and had an attached home box, and their forays beginning from the home box through arena space were analyzed; this task is self-directed, non reinforced. Middle-aged rats receiving ampakine or vehicle were initially tested in the apparatus beginning 5 weeks following the initiation of drug treatment to assess changes in their behavior, and then reassessed 4, 7, and 14 days later to evaluate long-term memory of the complex environment; testing was prior to the daily CX929 treatment to preclude circulating drug effects. For both groups of rats, the average numbers of forays in the apparatus were similar on the first day of testing. On subsequent test days the ampakine treated rats exhibited a marked reduction in total number of forays, whereas the vehicle group did not show this pattern and numbers of forays remained high even with the additional experience. A potential confound to these findings could be if the CX929 had affected arousal, but measures of distance travelled during explorations were not different between drug and vehicle treated groups suggesting little to no effect on arousal. Likewise, ampakine treated rats did not exhibit anxiety related behaviors such as preference for darken spaces or preference for being near walls as opposed to open spaces in the arena; both measures were equivalent between ampakine and vehicle treated groups. The results suggest that the change in exploration across days for the CX929 group reflected enhanced learning during the initial session that did not occur in the vehicle treated group. Next, it was evaluated whether there were differences in the 25 movement patterns between the two groups of rats within the arena using a Markov sequence analysis; using this technique, predictions errors were calculated for an animal's location at different times in the future based on probabilities from its own past behavior for single transitions between sites within the arena (van der Heijden et al., 1990). These analyses revealed that the prediction errors for ampakine treated rats were significantly less than vehicle treated rats across the testing days, indicating that CX929 treatment helped to organize the exploratory behavior of the middle-aged rats into predictable patterns. Finally, consistent with the improvements in behavior, there were also marked improvements in hippocampal CA1 LTP and a restoration of neuronal cytoarchitecture, including increased dendritic branching and spine growth, in the CX929-treated rats.
Fighting over crumbs at these levels and on the "Expert Market".
Absolutely....
Reality though is they need to just get current and explain why they gave up a solid track record with filings and information provided to the investing public.
Also update the entire website with current information on corporate and pipeline matters.
Coalesce all these publication efforts to understand how extensive the body of work is.
Approaching Q4 in a week and they have stated the DOD phase 2 should kick off sometime in Q4. Probably the greatest chance they have had in years to take their ampakine program and introduce to investing and potential collaborating public. Also the Tier 3 NIH gabakine preclinicals leading into the consultant hire for grant funding and project support. Investing and potential collaborating public might be a bit interested in something that has an initial look of being superior to standard of care in many facets.
So much potential.. so much silence.. and time keeps on ticking...
I rather if they update us on the progress on the dod clinical trails or atleast issue some sort of indication it’s under way
A few here are really sneaky
Yep 2025 will be huge year, as assuming this upcoming phase 2 SCI is successful, with all their publication efforts recently, they must be driving to exploit the ampakine platform into many more human trials. I know they have mentioned various orphan indications, but the big one is ADHD which is huge market and has shown past human trial success.
On top of that the gabakine KRM-ll-81 is superior to all in preclinicals, so how quickly they can secure grant funding and get that compound into humans will dictate how exponential the ride is for those of us who are invested here.
It should be noted that insiders and convertible holders have their shares at .0015 or higher. Warrants attached to loans to company need to see multiples of that to cover their loan basis. And those are bare minimum targets to see any reward for their risk. I would speculate we would see this well into the pennies before much is taken off the table by those who are invested in the science here and want to see this through various human clinical trials.
lol no wonder they are advertising that. Make sense advice jaded by the color envy
Eh, I doubt there are algorithms or traders that dumb to be short shares on a pharma stock with DOD funding a phase 2 trial next quarter. Which starts in about a week.
Of note the ampakine platform sold for 10 million + milestones a decade+ ago. RSPI got them all back and the technology to implement is stronger now and in combo with the government funding for phase 2 is readying for prime time, IMO. Maybe explains why there has been significant efforts to document and publicize all their efforts related to ampakines. Pouring fuel in the boosters.
Sell ur shares then boss. Holding mine till diamonds start erupting or the ground goes completely cold
Ur the only one that wants to get out this low be our guest lol
Yea but once you sold your shares you can’t buy them back. If this goes out of EM we trading multiples higher.
It's very hard to find a buyers willing to slap ask in expert market! It come and go...u need take advantage of it
Jus, I’m in RSPI for much higher prices.
.0004 x .002....u shoulda put sell .0019!! That buyer bid .0013 has no patience ..he slap ask!
Lol how tf is there naked shares on EM beyond wild😂
Now 10,000 lol at 0.002.
It’s showing 20,000 atm, but there is a 15min delay. Give me a second.
How much is on the ask now, should’ve blown past 002
Nice about one million bought at 0.002.
LT - I think you are right... 2025: hang on we are in for a helluva ride. RSPI has tapped into the most creative aspect of biotech - the graduate student. And by making available all of the ampakines for incredible prices. As I noted previously this preclinical research on the cheap is now poised for a number of molecules to go into more advance preclinical (e.g., monkeys) or clinical trials.
Interesting.
The Respire Pipeline only shows CX-1942 in addition to 717 and 1739 which are both shown as in phase 2. There clearly must be some impetus to essentially document and publicize all this past work and efforts related to the ampakine platform. It is not like they just did these studies in the past few years, much of the efforts look to be from quite awhile ago.
With the phase 2 SCI upcoming... logically there must be some preps for what is next assuming success. Phase 3, phase 2 ADHD? other orphan indications? Feels like they are prepping for a significant influx of interest in their ampakines!!!
It appears this paper is expanding that definition to include the two ampakines, one biologically active and the other inactive that together have a synergic effect to produce or accentuate a new or expanded biological effect. Synergistic: the interaction of two or more drugs when their combined effect is greater than the sum of the effects seen when each drug is given alone. I don't recall where I got the information that CX-1763 was no longer being investigated - obviously that source was wrong.
Any indication when this ticker will come back online via Market makers ? What's the hold up ?
In future text books, RSPI will be listed as an Anomoly.
Followers
|
347
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
51719
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators DTGoody crazy horse 0 Lime Time archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
Form Type | Received | Period End Date | Report |
---|---|---|---|
8-K | 07/08/2024 | 07/02/2024 | PDFRTFHTMLXLS |
8-K | 05/29/2024 | 05/29/2024 | PDFRTFHTMLXLS |
8-K | 04/16/2024 | 04/10/2024 | PDFRTFHTMLXLS |
NT 10-K | 04/01/2024 | 12/31/2023 | PDFRTFHTMLXLS |
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |